CRSP CRISPR Therapeutics AG - Common Shares
$56,87
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 3, 2026
52 Haftlık Aralık
$44–$78
37% of range
Analist Derecelendirmesi
HOLD
29 analysts
Fiyat Hedefi
$88
+54% upside
P/E (TTM)
-8.8
ROE
-32.0%
Net Kâr Marjı
-16569.8%
CRISPR Therapeutics AG - Common Shares Hakkında Wikipedia'dan şirket genel bakışı
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Devamını oku
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
CRSP Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$56.87
Piyasa Değeri
$5.45B
P/E (TTM)
-8.8
EPS (TTM)
$-6.47
Gelir (TTM)
$4M
Temettü Verimi
—
ROE
-32.0%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$44 – $78
CRSP Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$4M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-6.47
2017-12-31
→
2025-12-31
Serbest Nakit Akışı
$-346M
2016-12-31
→
2025-12-31
Marjlar
-16569.8%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
CRSP
Akran Ortalaması
P/E (TTM)
-8.8
—
P/S (TTM) (F/S (TTM))
1553.7
56.3
P/B (F/D)
2.8
3.0
Price / FCF (Fiyat / Serbest Nakit Akışı)
-15.8
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
CRSP
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
-18933.7%
—
Net Profit Margin (Net Kâr Marjı)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
CRSP
Akran Ortalaması
Current Ratio (Cari Oran)
13.3
6.7
Quick Ratio (Cari Oran)
13.2
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
CRSP
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
-90.6%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
43.1%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
37.3%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
CRSP
Akran Ortalaması
CRSP Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
29 analist
- Güçlü Al 6 20,7%
- Al 11 37,9%
- Tut 12 41,4%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
18 analist · 2026-08-15
Medyan
$80.00
Şimdi
$56.87
Düşük
$44.00
Yüksek
$291.00
Medyan hedef
$80.00
+40,7%
Ortalama hedef
$87.56
+54,0%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.01%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 30 Haziran 2026 | $-0.94 | $-1.22 | 0.28% |
| 31 Mart 2026 | $-1.28 | $-1.25 | -0.03% |
| 31 Aralık 2025 | $-1.37 | $-1.18 | -0.19% |
| 30 Eylül 2025 | $-1.17 | $-1.29 | 0.12% |
| 30 Haziran 2025 | $-1.29 | $-1.45 | 0.16% |
| 31 Mart 2025 | $-1.58 | $-1.28 | -0.30% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 15
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Bilanço 25
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Nakit Akışı 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Likidite ve Solventlik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Verimlilik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Gelir Tablosu 14
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Bilanço 25
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Nakit Akışı 11
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Kârlılık 7
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Verimlilik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Değerleme (TTM) 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $4M | $37M | $371M | $1M | $915M |
| Faaliyet Kâr Marjı % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Net Gelir | $-582M | $-366M | $-154M | $-650M | $378M |
| Seyreltilmiş Hisse Başı Kâr | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Cari Oran | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-346M | $-145M | $-270M | $-533M | $457M |
Son Haberler Bu şirketten bahseden son manşetler
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- CRISPR Therapeutics Hissesi Absürt Derecede Ucuz -- İşte Analistlerin %437'lik Yükseliş Potansiyeli Görmesinin Nedeni
- Mega-Cap Büyüme Liderliği mi Yoksa Küçük Sermayeli Büyüme Potansiyeli mi? VUG vs VBK
- 1 En İyi Wall Street Analisti CRISPR Therapeutics'in İki Katından Fazla Artabileceğini Düşünüyor. Hisseyi Avuç Avuç Satın Almalı mısınız?
- Tespit Edilen Dikkat Çekici ETF Çıkışı - ARKK, CRSP, TEM, HOOD
- Bu Biyoteknoloji Şirketinin Tüm Terapötik Alanını Yeniden Tanımlayabilecek Bir Aday Kadrosu Var
- Cathie Wood İndirim Avına Çıkıyor: Yeni Aldığı 2 Hisse Senedi
- Bu Biyoteknoloji Hissesi, Bir Milyoner Oluşturma Konumunu İnşa Etmek İçin En İyi Şansınız mı?
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 573 dosya · $3.3B toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 89 (0 önceki Ç'ye göre) | 47 (-13 önceki Ç'ye göre) | 148 (-24 önceki Ç'ye göre) | 145 (+21 önceki Ç'ye göre) | +5.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| ARK Investment Management LLC | $515.999.631 | 9.460.939 | 15,58% | Hisse senetleri |
| Orbis Allan Gray Ltd | $296.334.582 | 5.433.344 | 8,95% | Hisse senetleri |
| Capital World Investors | $259.039.094 | 4.749.525 | 7,82% | Hisse senetleri |
| STATE STREET CORP | $235.703.664 | 4.321.666 | 7,12% | Hisse senetleri |
| GSK plc | $175.652.997 | 3.220.627 | 5,30% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $117.453.717 | 2.153.015 | 3,55% | Hisse senetleri |
| SR One Capital Management, LP | $111.194.134 | 2.038.763 | 3,36% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $108.459.389 | 1.988.621 | 3,27% | Hisse senetleri |
| Sumitomo Mitsui Trust Group, Inc. | $93.848.832 | 1.720.734 | 2,83% | Hisse senetleri |
| Amova Asset Management Americas, Inc. | $93.762.487 | 1.720.097 | 2,83% | Hisse senetleri |
| EcoR1 Capital, LLC | $75.771.113 | 1.389.276 | 2,29% | Hisse senetleri |
| Capital International Investors | $69.178.918 | 1.268.407 | 2,09% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $64.457.935 | 1.181.847 | 1,95% | Hisse senetleri |
| NEA Management Company, LLC | $57.734.408 | 1.058.570 | 1,74% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57.694.430 | 1.057.837 | 1,74% | Hisse senetleri |
| FMR LLC | $53.577.751 | 982.357 | 1,62% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $48.748.506 | 893.812 | 1,47% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35.380.807 | 648.713 | 1,07% | Hisse senetleri |
| UBS Group AG | $32.419.612 | 594.419 | 0,98% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $31.089.982 | 570.040 | 0,94% | Hisse senetleri |
| VANGUARD GROUP INC | $27.714.225 | 528.494 | 0,84% | Hisse senetleri |
| CITADEL ADVISORS LLC | $25.404.514 | 465.796 | 0,77% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $23.509.740 | 431.055 | 0,71% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23.298.288 | 427.178 | 0,70% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $20.836.025 | 382.032 | 0,63% | Hisse senetleri |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20.833.789 | 381.991 | 0,63% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18.456.336 | 338.400 | 0,56% | Satım opsiyonu |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17.763.678 | 325.700 | 0,54% | Alım opsiyonu |
| Logos Global Management LP | $16.362.000 | 300.000 | 0,49% | Hisse senetleri |
| CITADEL ADVISORS LLC | $15.822.054 | 290.100 | 0,48% | Satım opsiyonu |
| Squarepoint Ops LLC | $15.641.472 | 286.789 | 0,47% | Hisse senetleri |
| NORGES BANK | $14.767.032 | 270.756 | 0,45% | Hisse senetleri |
| CITADEL ADVISORS LLC | $13.973.148 | 256.200 | 0,42% | Alım opsiyonu |
| GOLDMAN SACHS GROUP INC | $12.748.193 | 233.740 | 0,38% | Hisse senetleri |
| JANE STREET GROUP, LLC | $12.566.016 | 230.400 | 0,38% | Alım opsiyonu |
| PEAK6 LLC | $11.633.382 | 213.300 | 0,35% | Satım opsiyonu |
| Swiss National Bank | $9.228.168 | 169.200 | 0,28% | Hisse senetleri |
| Susquehanna Portfolio Strategies, LLC | $8.945.978 | 164.026 | 0,27% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $8.516.256 | 162.400 | 0,26% | Hisse senetleri |
| LPL Financial LLC | $8.376.280 | 153.581 | 0,25% | Hisse senetleri |
| Bank of New York Mellon Corp | $8.337.366 | 152.867 | 0,25% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $8.301.261 | 152.205 | 0,25% | Hisse senetleri |
| Versant Venture Management, LLC | $8.117.243 | 148.831 | 0,25% | Hisse senetleri |
| Pictet Asset Management Holding SA | $7.989.776 | 142.213 | 0,24% | Hisse senetleri |
| Life Cycle Investment Partners Ltd | $7.836.962 | 143.692 | 0,24% | Hisse senetleri |
| TD Asset Management Inc | $7.777.513 | 142.602 | 0,23% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $7.606.257 | 139.462 | 0,23% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $7.230.750 | 132.577 | 0,22% | Hisse senetleri |
| RHUMBLINE ADVISERS | $6.627.197 | 121.511 | 0,20% | Hisse senetleri |
| SFE Investment Counsel | $6.229.434 | 16.700 | 0,19% | Satım opsiyonu |
| Private Advisor Group, LLC | $6.060.980 | 111.129 | 0,18% | Hisse senetleri |
| EverSource Wealth Advisors, LLC | $6.032.669 | 110.610 | 0,18% | Hisse senetleri |
| CONGRESS ASSET MANAGEMENT CO | $5.969.567 | 109.453 | 0,18% | Hisse senetleri |
| BlackRock, Inc. | $5.937.061 | 108.857 | 0,18% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $5.901.228 | 108.200 | 0,18% | Alım opsiyonu |
| Campbell & CO Investment Adviser LLC | $5.864.632 | 107.529 | 0,18% | Hisse senetleri |
| JANE STREET GROUP, LLC | $5.852.142 | 107.300 | 0,18% | Satım opsiyonu |
| California Public Employees Retirement System | $5.599.567 | 102.669 | 0,17% | Hisse senetleri |
| CAPITAL INTERNATIONAL SARL | $5.521.521 | 101.238 | 0,17% | Hisse senetleri |
| Affinity Asset Advisors, LLC | $5.454.000 | 100.000 | 0,16% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $5.439.011 | 114.337 | 0,16% | Hisse senetleri |
| CLOUGH CAPITAL PARTNERS L P | $5.363.300 | 98.337 | 0,16% | Hisse senetleri |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5.172.465 | 94.838 | 0,16% | Hisse senetleri |
| Slow Capital, Inc. | $5.066.439 | 92.894 | 0,15% | Hisse senetleri |
| CAPITAL FUND MANAGEMENT S.A. | $4.867.258 | 89.242 | 0,15% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4.815.606 | 101.232 | 0,15% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $4.720.437 | 86.550 | 0,14% | Hisse senetleri |
| GROUP ONE TRADING LLC | $4.638.082 | 85.040 | 0,14% | Hisse senetleri |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4.575.742 | 83.897 | 0,14% | Hisse senetleri |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4.502.113 | 82.547 | 0,14% | Hisse senetleri |
| Concurrent Investment Advisors, LLC | $4.497.728 | 82.467 | 0,14% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $4.309.151 | 79.009 | 0,13% | Hisse senetleri |
| Fisher Asset Management, LLC | $4.251.957 | 77.960 | 0,13% | Hisse senetleri |
| Trexquant Investment LP | $4.225.268 | 77.471 | 0,13% | Hisse senetleri |
| COMMONWEALTH EQUITY SERVICES, LLC | $4.194.122 | 76.900 | 0,13% | Hisse senetleri |
| JONES FINANCIAL COMPANIES LLLP | $4.055.652 | 73.847 | 0,12% | Hisse senetleri |
| Man Group plc | $3.992.001 | 73.194 | 0,12% | Hisse senetleri |
| PEAK6 LLC | $3.834.162 | 70.300 | 0,12% | Alım opsiyonu |
| ENVESTNET ASSET MANAGEMENT INC | $3.822.196 | 70.081 | 0,12% | Hisse senetleri |
| ALGERT GLOBAL LLC | $3.593.095 | 65.880 | 0,11% | Hisse senetleri |
| Walleye Trading LLC | $3.528.738 | 64.700 | 0,11% | Satım opsiyonu |
| MILLENNIUM MANAGEMENT LLC | $3.146.958 | 57.700 | 0,10% | Alım opsiyonu |
| CAPITAL INTERNATIONAL LTD /CA/ | $3.057.840 | 56.066 | 0,09% | Hisse senetleri |
| NOMURA HOLDINGS INC | $3.055.713 | 56.027 | 0,09% | Hisse senetleri |
| Rafferty Asset Management, LLC | $3.045.132 | 55.833 | 0,09% | Hisse senetleri |
| Green Alpha Advisors, LLC | $3.043.550 | 55.804 | 0,09% | Hisse senetleri |
| Walleye Trading LLC | $3.005.154 | 55.100 | 0,09% | Alım opsiyonu |
| Caption Management, LLC | $2.999.700 | 55.000 | 0,09% | Alım opsiyonu |
| MetLife Investment Management, LLC | $2.958.413 | 54.243 | 0,09% | Hisse senetleri |
| BENJAMIN EDWARDS INC | $2.956.845 | 54.216 | 0,09% | Hisse senetleri |
| Quantinno Capital Management LP | $2.869.349 | 52.610 | 0,09% | Hisse senetleri |
| Cetera Investment Advisers | $2.856.133 | 52.368 | 0,09% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.788.521 | 51.128 | 0,08% | Hisse senetleri |
| CITIGROUP INC | $2.781.540 | 51.000 | 0,08% | Alım opsiyonu |
| CITIGROUP INC | $2.781.540 | 51.000 | 0,08% | Satım opsiyonu |
| WOLVERINE ASSET MANAGEMENT LLC | $2.727.000 | 50.000 | 0,08% | Satım opsiyonu |
| OSAIC HOLDINGS, INC. | $2.693.150 | 49.381 | 0,08% | Hisse senetleri |
| Privium Fund Management B.V. | $2.452.882 | 44.974 | 0,07% | Hisse senetleri |
| CANADA PENSION PLAN INVESTMENT BOARD | $2.394.306 | 43.900 | 0,07% | Hisse senetleri |
| TUDOR INVESTMENT CORP ET AL | $2.318.604 | 42.512 | 0,07% | Hisse senetleri |
Şirket yöneticileri 32 içeriden öğrenenler · 12 yöneticiler · 16 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 Mart 2026 M | 255.501 | 0 | 9 | $-10.756.932 |
| Brendan Smith | Chief Financial Officer | 18 Şubat 2023 M | 5.072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 Mart 2021 M | 1.891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 Mart 2025 M | 10.544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 Ağustos 2022 A | 26.797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 29 Mayıs 2026 A | 19.357 | 1 | 2 | $-312.892 |
| James R. Kasinger | General Counsel and Secretary | 29 Mayıs 2026 A | 94.308 | 0 | 5 | $-645.902 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 Ekim 2023 A | 4.411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 03 Aralık 2021 M | 52.364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 Ocak 2018 M | 25.204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 Haziran 2017 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 Ekim 2016 C | 505.617 | 0 | 0 | $0 |
| Christian Rommel | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Douglas A Treco | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Briggs Morrison | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Katherine A High | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Ali Behbahani | Yönetim kurulu üyesi | 05 Haziran 2026 A | 14 | 0 | 0 | $0 |
| John Greene | Yönetim kurulu üyesi | 05 Haziran 2026 A | 7.000 | 0 | 0 | $0 |
| Simeon George | Yönetim kurulu üyesi | 05 Haziran 2026 A | 1.730.179 | 0 | 0 | $0 |
| Maria Fardis | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | Yönetim kurulu üyesi | 05 Haziran 2026 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Yönetim kurulu üyesi | 09 Haziran 2022 A | 148.831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Yönetim kurulu üyesi | 19 Kasım 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Yönetim kurulu üyesi | 18 Aralık 2018 S | 1.171.268 | 0 | 0 | $0 |
| Thomas Woiwode | Yönetim kurulu üyesi | 15 Haziran 2018 A | 640.014 | 0 | 0 | $0 |
| Anthony N Coles | Yönetim kurulu üyesi | 31 Mayıs 2017 A | 70.000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% sahip | 04 Aralık 2017 S | 3.722.534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% sahip | 24 Ekim 2016 C | 744.380 | 0 | 0 | $0 |
| GSK plc | 10% sahip | 24 Ekim 2016 C | 3.220.627 | 0 | 0 | $0 |
| Raju Prasad | — | 07 Ağustos 2026 G | 14.815 | 0 | 10 | $-5.100.841 |
| Rodger Novak | — | 30 Haziran 2021 S | 573.007 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 6 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 başvurular | 16 Şubat 2021 | — | İlk başvuru | — | SEC |
| GlaxoSmithKline plc ×5 başvurular | 10 Temmuz 2020 | — | İlk başvuru | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 başvurular | 04 Şubat 2020 | — | İlk başvuru | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 başvurular | 07 Haziran 2019 | — | İlk başvuru | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 başvurular | 08 Şubat 2018 | — | İlk başvuru | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 başvurular | 16 Ocak 2018 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 32 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| GNOM · Global X Funds | 3,85% | 38.191 NS | 31 Mayıs 2026 | N-PORT |
| IDNA · iShares Trust | 1,63% | 62.247 SH | 08 Ağustos 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,98% | 97.235 NS | 30 Nisan 2026 | N-PORT |
| IBB · iShares Trust | 0,36% | 658.537 SH | 08 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 5.248 SH | 08 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70.696 SH | 08 Ağustos 2026 | Günlük |
| IWN · iShares Trust | 0,27% | 752.223 SH | 08 Ağustos 2026 | Günlük |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,21% | 104.016 NS | 31 Mayıs 2026 | N-PORT |
| ISCV · iShares Trust | 0,15% | 20.568 SH | 08 Ağustos 2026 | Günlük |
| IWM · iShares Trust | 0,15% | 2.353.025 SH | 08 Ağustos 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536.446 SH | 08 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,15% | 39.589 NS | 30 Nisan 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,10% | 6.636 SH | 08 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | 0,07% | 4.136 SH | 08 Ağustos 2026 | Günlük |
| SMLF · iShares Trust | 0,07% | 57.970 SH | 08 Ağustos 2026 | Günlük |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1.106.455 SH | 08 Ağustos 2026 | Günlük |
| ESML · iShares Trust | 0,06% | 33.283 SH | 08 Ağustos 2026 | Günlük |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,06% | 108 NS | 31 Mayıs 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 5.486 SH | 08 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13.170 SH | 08 Ağustos 2026 | Günlük |
| IWO · iShares Trust | 0,04% | 109.974 SH | 08 Ağustos 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1.736 SH | 08 Ağustos 2026 | Günlük |
| XT · iShares Trust | 0,03% | 21.837 SH | 08 Ağustos 2026 | Günlük |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,03% | 3.509 NS | 31 Mayıs 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7.774 SH | 08 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20.627 SH | 08 Ağustos 2026 | Günlük |
| IYY · iShares Trust | 0,01% | 4.231 SH | 08 Ağustos 2026 | Günlük |
| ITOT · iShares Trust | 0,01% | 128.511 SH | 08 Ağustos 2026 | Günlük |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,01% | 15.609 NS | 31 Mayıs 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 25.457 SH | 08 Ağustos 2026 | Günlük |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 289 NS | 31 Mayıs 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75.392 SH | 08 Ağustos 2026 | Günlük |